E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with coronary artery disease who suffer from myocardial malperfusion and continue to experience angina despite maximal medical and revascularization therapy are called "no-option" patients. |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with coronary artery disease who suffer from myocardial malperfusion and continue to experience angina despite maximal medical and revascularization therapy are called "no-option" patients. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The aim of this study is to prospectively investigate if intermittent Phosphodiesterase 5 inhibition for 15 weeks improves myocardial perfusion by angiogenesis in patients with therapy refractory myocardial ischemia due to coronary artery disease judged to be unsuitable for surgical or percutaneous revascularisation. |
|
E.2.2 | Secondary objectives of the trial |
The aim of this study is to prospectively investigate if intermittent Phosphodiesterase 5 inhibition for 15 weeks improves myocardial perfusion by angiogenesis in patients with therapy refractory myocardial ischemia due to coronary artery disease judged to be unsuitable for surgical or percutaneous revascularisation. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Stable angina pectoris 2) Evidence for myocardial ischemia according to the presence of one or more of the followings: - Typical angina during exercise test or - Significant reversible perfusion defects on dipyridamole myocardial radionuclide study 3) Coronary artery disease of at least one large epicardial coronary artery with ≥70% stenosis remaining from which new collaterals/vessels could be supplied 4) Coronary artery disease judged to be unsuitable for surgical or percutaneous revascularisation due to extensive atherosclerosis 5) Optimized anti-ischemic drug therapy (including beta-blocker therapy with at least 50% target dose) 6) Subject must be willing and able to give informed consent Eligible patients must fulfil all 6 inclusion criteria.
|
|
E.4 | Principal exclusion criteria |
1) STEMI or NSTEMI within the past 3 months 2) Revascularisation procedures within the last 3 months 3) Severely reduced systolic left ventricular function EF < 30% 4) Systolic blood pressure <120mmHg 5) Chronic renal insufficiency with a serum creatinine >2.5mg/dl 6) Diabetes mellitus with proliferative retinopathy 7) Diagnosed or suspected cancer 8) Chronic inflammatory disease 9) Therapy with nitrates and nicorandil 10) Women who are pregnant or lactating 11) Patients with a total occluded vessel and reversible perfusion defects at the marginal zone of scare tissue if they have no additional stenosed vessels causing significant reversible perfusion defects. 12) Patients with a total occluded vessel and perfusion defect at rest despite evidence of vital myocardium, if they have no additional stenosed vessels causing significant reversible perfusion defects. Eligible patients must demonstrate none of the exclusion criteria.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Endpoint: - Total exercise duration (bicycle exercise testing)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
baseline after 12 weeks of treatment 4 weeks after end of treatment |
|
E.5.2 | Secondary end point(s) |
Secondary Endpoints: - Time to 1mm ST-segment depression (bicycle exercise testing) - Time to limiting angina (bicycle exercise testing) - Myocardial blood flow (PET) - Left ventricular ejection fraction (PET) - Mean angina frequency per week - Score Seattle Angina Questionnaire - Natriuretic peptides - Markers of angiogenesis
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
baseline after 12 weeks of treatment 4 weeks after end of treatment |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Sample size was calculated to detect a difference in mean exercise duration between groups after 12 weeks of 88 seconds, assuming a within group standard deviation of 116 seconds. These assumptions, an alpha <0.05 and a power of 0.8 for a two-sided independent group comparison (t-test) yield a sample size of 56 (28 in each group). Including a safety margin of approximately 7%, the study aims to recruit 60 patients. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |